{"brief_title": "Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals", "brief_summary": "To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour infusion of paclitaxel every 14 days. To evaluate the clinical benefit of paclitaxel in this patient population by evaluating self-reported responses to the Symptom Distress Scale and by documenting and evaluating any changes in their lymphedema, pain and disfiguring facial lesions.", "detailed_description": "Patients are treated with paclitaxel intravenously every 2 weeks up to 10 courses. Patients who achieve a complete response receive 2 additional courses those who achieve partial response or stabilization, continue therapy until progression.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Paclitaxel", "criteria": "Inclusion Criteria Patients must have: - Microscopically confirmed diagnosis of KS associated with HIV for which systematic therapy is medically indicated by the presence of at least one of the following: A. >= 25 mucocutaneous (mouth or skin) lesions. B. Symptomatic visceral involvement. C. Symptomatic lymphedema (pain). - Minimum of 5 clearly measurably cutaneous lesions by physical exam or measurable disease by X-ray, CT or MRI. - Failed at least one systemic chemotherapy regimen. Exclusion Criteria Co-existing Condition: Patients with the following conditions and symptoms are excluded: - Less than 2 weeks since major surgery. - Serious uncontrolled infection. NOTE: - Must be ruled out by thorough work-up in patients with unexplained fevers, night sweats, or involuntary weight loss of more than 10% normal weight. - Leukopenia. - Thrombocytopenia. Patients with the following prior conditions are excluded: - History of angina or myocardial infarction within the past 6 months. - Second degree or third degree atrioventricular block without a pacemaker. - Congestive heart failure (poorly controlled). - History of prior malignancy except: Completely excised in situ, carcinoma of the cervix or nonmelanomatous skin cancer. Curatively treated other malignancy with no evidence of disease for at least 5 years. Prior Medication: Excluded: Prior taxane therapy. Required: - At least one systemic chemotherapy regimen that failed to maintain significant benefit. NOTE: - Intralesional chemotherapy regimens are not considered as prior chemotherapy. - At least 2 weeks since last dose of prior systemic chemotherapy.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002189.xml"}